WAVEMAN · COMPANY

CPRX · Catalyst Pharmaceuticals, Inc.

LIVE

TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475TEAM-2.62% 13F +440META+1.00% 13F +2,694RCG+0.35% CLUSTERUTHR-0.54% 13F +425CRWV+5.68% 13F +694CRM-1.97% 13F +1,019CVNA+1.58% 13F +795TPL-1.11% 13F +444NET-1.96% 13F +711MSTR-1.39% 13F +527DELL+1.50% 13F +1,204CRWD-0.87% 13F +1,383ANET+1.22% 13F +1,324COIN-4.18% 13F +475

← ALL COMPANIES

CPRX

Name: CATALYST PHARMACEUTICALS, INC. (CPRX) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

CATALYST PHARMACEUTICALS, INC.

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001369568

SEC FILINGS☆ WATCH

INSIDER NET · 180D

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

222

13F, latest reported quarter

REVENUE GROWTH

+19.8%

XBRL, annual

NET MARGIN

36.4%

CONVERSIONS · 180D

codes C/M, not in net · no price filed

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

no Form 4 purchases or sales on file

CONGRESS

no member of Congress has reported trading it

FUNDS

222 funds added or opened last quarter

more than 89% of Pharma & Biotech

REVENUE

+19.8% year over year

more than 69% of Pharma & Biotech

MARGIN

36.4% net margin

more than 94% of Pharma & Biotech

BUYBACKS

$14.6M repurchased, FY to 2026-03-31

below 66% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

222 funds added or opened positions in the latest 13F quarter, of 398 holders.

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

The complete filing record, in one place.

The record shows 222 funds added last quarter. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

UTHR CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

No insider purchases or sales are on record for CATALYST PHARMACEUTICALS, INC. in the period covered. Source: SEC Form 4 filings, as of 2026-09-06.

INSIDER

FILED

VALUE

Harper Molly

Director

SELL

2025-12-12

4,473.0

$106.1K

Harper Molly

Director

SELL

2025-12-12

15,527.0

$360.2K

Harper Molly

Director

SELL

2025-12-12

6,746.0

$155.6K

Del Carmen Jeffrey

Chief Commercial Officer

SELL

2025-11-26

10,983.0

$256.2K

Elsbernd Brian

Chief Compliance/Legal Officer

SELL

2025-11-12

40,000.0

$908.0K

137 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 132 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

19,158,785.0 sh

$602.2M

STATE STREET CORP

7,627,036.0 sh

$239.7M

AMERICAN CENTURY COMPANIES INC

5,553,921.0 sh

$174.6M

VANGUARD CAPITAL MANAGEMENT LLC

5,135,345.0 sh

$161.4M

DIMENSIONAL FUND ADVISORS LP

3,634,171.0 sh

$114.2M

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

FORM 144

No planned-sale notices

No insider has notified an intent to sell. This is the panel to watch after a run-up.

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Quantified Common Ground Fund

$9.4M POSITION · AS OF 2026-03-31

8.0%

StockSnips AI-Powered Sentiment US All Cap ETF

$669.3K POSITION · AS OF 2026-04-30

3.5%

Invesco Biotechnology & Genome ETF

$8.2M POSITION · AS OF 2026-04-30

3.3%

Tanaka Growth Fund

$1.2M POSITION · AS OF 2026-02-28

3.3%

Third Avenue Small-Cap Value Fund

$5.9M POSITION · AS OF 2026-04-30

2.9%

Total Market Plus Equity Portfolio

$721.9K POSITION · AS OF 2026-04-30

2.9%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 5 registered trials, 1 still enrolling or running — a status change here is dated weeks before the press release

Phase 2

0 ACTIVE

Phase 3

0 ACTIVE

Not applicable

1 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Richard J. Daly

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2024

$7.8M

$12.9M

$3.7M

+457%

-12%

2023

$2.1M

$1.0M

$2.3M

+348%

-46%

2022

$6.9M

$17.5M

$2.7M

+396%

-31%

2021

$2.1M

$5.4M

$1.4M

+81%

-6%

2020

$1.8M

$1.5M

$1.2M

-11%

+13%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$589.0M	$491.7M	$398.2M	$214.2M
OPERATING INCOME	$257.8M	$195.1M	$86.8M	$101.8M
NET INCOME	$214.3M	$163.9M	$71.4M	$83.1M
EPS (DILUTED)	1.68	1.31	0.63	0.75
OPERATING CASH FLOW	$208.7M	$239.8M	$143.6M	$116.0M
CASH	$709.2M	$517.6M	$137.6M	$298.4M
BUYBACKS	$25.3M	$0	$0	$6.9M

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-06 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE